Background: The impact of uric acid as a stand-alone risk factor for non-communicable illness has been debated for decades. Strong free radical scavengers like hydroxyl ions, peroxynitrite, and other antioxidants like ascorbic acid are all scavenged by serum uric acid. Neuroprotective agents include uric acid and its connection to ischemic stroke is still debatable. Therefore, the current study tried to evaluate the serum uric levels in acute ischemic stroke patients.

Methods: Patients with acute stroke were included in the trial, thus if rTPA was given to them, it was noted. The patient's baseline blood pressure was taken (in a supine position). All acute stroke patients had blood drawn within 24 hours of admission to assess their lipid profiles, fasting blood sugar levels, and uric acid levels. A neurologist assessed each patient, and computer tomography (CT) and magnetic resonance imaging were used to distinguish between ischemic stroke and other types of stroke (MRI).

Results: Serum UA levels were found to be significantly higher in stroke patients, with 77.5 percent of patients having high levels (>6 mg/dL) compared to 30.0 percent of controls. When compared to the controls, the mean serum UA level in patients was considerably higher (p=0.0212). Multiple logistic regression analysis was used to determine the relationship between serum UA levels and outcome. Independent of other prognostic criteria, patients with high serum UA levels had a significantly worse outcome.

Conclusion: A significant relationship exists between high serum UA levels and ischemic stroke, stroke subtypes (excluding lacunar stroke), and poor outcomes. Finding and managing modifiable risk factors for stroke has advanced quite a bit. Hyperuricemia could be therapeutically targeted in the same manner that other risk factors, such as dyslipidemia and blood pressure, are regularly treated after stroke.